108 related articles for article (PubMed ID: 23732371)
21. Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab.
Hegedüs L; Smith TJ; Douglas RS; Nielsen CH
Clin Endocrinol (Oxf); 2011 Jan; 74(1):1-8. PubMed ID: 20455896
[TBL] [Abstract][Full Text] [Related]
22. Rituximab for thyroid eye disease.
Silkiss RZ; Reier A; Coleman M; Lauer SA
Ophthalmic Plast Reconstr Surg; 2010; 26(5):310-4. PubMed ID: 20562667
[TBL] [Abstract][Full Text] [Related]
23. Clinical and immunological changes in patients with active moderate-to-severe Graves' orbitopathy treated with very low-dose rituximab.
Karasek D; Cibickova L; Karhanova M; Kalitova J; Schovanek J; Frysak Z
Endokrynol Pol; 2017; 68(5):498-504. PubMed ID: 28660988
[TBL] [Abstract][Full Text] [Related]
24. Monoclonal anti-TNFalpha antibody (infliximab) in the treatment of patient with thyroid associated ophthalmopathy.
Komorowski J; Jankiewicz-Wika J; Siejka A; Lawnicka H; Kłysik A; Goś R; Majos A; Stefańczyk L; Stepień H
Klin Oczna; 2007; 109(10-12):457-60. PubMed ID: 18488396
[TBL] [Abstract][Full Text] [Related]
25. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab).
Heiligenhaus A; Miserocchi E; Heinz C; Gerloni V; Kotaniemi K
Rheumatology (Oxford); 2011 Aug; 50(8):1390-4. PubMed ID: 21378109
[TBL] [Abstract][Full Text] [Related]
26. Severe unilateral orbitopathy in a patient with Hashimoto's thyroiditis - a case report.
Cyranska-Chyrek E; Olejarz M; Szczepanek-Parulska E; Stajgis P; Pioch A; Ruchala M
BMC Ophthalmol; 2019 Jan; 19(1):9. PubMed ID: 30621642
[TBL] [Abstract][Full Text] [Related]
27. Orbital B-lymphocyte depletion in a treatment failure of rituximab for thyroid eye disease.
Gess AJ; Silkiss RZ
Ophthalmic Plast Reconstr Surg; 2014; 30(1):e11-3. PubMed ID: 23531951
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of rituximab in patients with Graves' orbitopathy: a retrospective multicenter nationwide study.
Deltour JB; d'Assigny Flamen M; Ladsous M; Giovansili L; Cariou B; Caron P; Drui D; Lebranchu P
Graefes Arch Clin Exp Ophthalmol; 2020 Sep; 258(9):2013-2021. PubMed ID: 32405700
[TBL] [Abstract][Full Text] [Related]
29. Quantitative analysis of orbital soft tissues on computed tomography to assess the activity of thyroid-associated orbitopathy.
Byun JS; Moon NJ; Lee JK
Graefes Arch Clin Exp Ophthalmol; 2017 Feb; 255(2):413-420. PubMed ID: 27838736
[TBL] [Abstract][Full Text] [Related]
30. Small dose of rituximab for graves orbitopathy: new insights into the mechanism of action.
Salvi M; Vannucchi G; Currò N; Introna M; Rossi S; Bonara P; Covelli D; Dazzi D; Guastella C; Pignataro L; Ratiglia R; Golay J; Beck-Peccoz P
Arch Ophthalmol; 2012 Jan; 130(1):122-4. PubMed ID: 22232486
[No Abstract] [Full Text] [Related]
31. [Treatment of Grave's ophthalmopathy with high doses of corticosteroids].
Cirić J; Zarković M; Stojanović M; Pepenezić Z; Randjelović G; Gligorović M; Trbojević B; Drezgić M; Nesović M
Srp Arh Celok Lek; 2000; 128(5-6):179-83. PubMed ID: 11089418
[TBL] [Abstract][Full Text] [Related]
32. The Pro 12 Ala PPAR gamma gene polymorphism: possible modifier of the activity and severity of thyroid-associated orbitopathy (TAO).
Alevizaki M; Mantzou E; Cimponeriu A; Saltiki K; Philippou G; Wiersinga W
Clin Endocrinol (Oxf); 2009 Mar; 70(3):464-8. PubMed ID: 18624999
[TBL] [Abstract][Full Text] [Related]
33. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris.
Behzad M; Möbs C; Kneisel A; Möller M; Hoyer J; Hertl M; Eming R
Br J Dermatol; 2012 Apr; 166(4):844-52. PubMed ID: 22092243
[TBL] [Abstract][Full Text] [Related]
34. [Treatment of thyroid-associated ophthalmopathy: comparative study between prednisone and COP therapy].
Min HY; Liu XP; Jiang RX; Lian L; Hu TS
Zhonghua Yan Ke Za Zhi; 2005 Sep; 41(9):781-5. PubMed ID: 16191342
[TBL] [Abstract][Full Text] [Related]
35. Retrobulbar injection of triamcinolone in thyroid associated orbitopathy.
Poonyathalang A; Preechawat P; Charoenkul W; Tangtrakul P
J Med Assoc Thai; 2005 Mar; 88(3):345-9. PubMed ID: 15962642
[TBL] [Abstract][Full Text] [Related]
36. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis.
De Vita S; Quartuccio L; Isola M; Mazzaro C; Scaini P; Lenzi M; Campanini M; Naclerio C; Tavoni A; Pietrogrande M; Ferri C; Mascia MT; Masolini P; Zabotti A; Maset M; Roccatello D; Zignego AL; Pioltelli P; Gabrielli A; Filippini D; Perrella O; Migliaresi S; Galli M; Bombardieri S; Monti G
Arthritis Rheum; 2012 Mar; 64(3):843-53. PubMed ID: 22147661
[TBL] [Abstract][Full Text] [Related]
37. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
[TBL] [Abstract][Full Text] [Related]
38. Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL.
Klepfish A; Gilles L; Ioannis K; Rachmilewitz EA; Schattner A
Ann N Y Acad Sci; 2009 Sep; 1173():865-73. PubMed ID: 19758239
[TBL] [Abstract][Full Text] [Related]
39. Thyroid-associated orbitopathy.
Tarabishy AB; Lewis CD; Perry JD
Ophthalmology; 2010 Sep; 117(9):1864; author reply 1864-5. PubMed ID: 20816259
[No Abstract] [Full Text] [Related]
40. Long-term multidisciplinary follow-up of unilateral thyroid-associated orbitopathy.
Daumerie Ch; Duprez T; Boschi A
Eur J Intern Med; 2008 Nov; 19(7):531-6. PubMed ID: 19013383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
